Clinically, elevated expression of MET proto-oncogene, receptor tyrosine kinase (MET) and AXL receptor tyrosine kinase (AXL) or their ligands correlates with worse status in pancreatic cancer patients [10,11]. The gene discussed is MET; the disease is familial pancreatic carcinoma.